Submitted: 27 Aug 2018
Accepted: 27 Dec 2018
First published online: 25 Feb 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Cardiovasc Thorac Res. 2019;11(1):35-42.
doi: 10.15171/jcvtr.2019.06
PMID: 31024670
PMCID: PMC6477105
  Abstract View: 245
  PDF Download: 213

Original Article

Mesenchymal stem cells from human amniotic membrane differentiate into cardiomyocytes and endothelial-like cells without improving cardiac function after surgical administration in rat model of chronic heart failure

Fazel Gorjipour 1, Ladan Hosseini-Gohari 1 * ORCiD, Alireza Alizadeh Ghavidel 2, Seyed Javad Hajimiresmaiel 3, Nasim Naderi 2, Amir Darbandi Azar 2, Hamidreza Pazoki-Toroudi 4 *

1 Cellular and Molecular Research center, Iran University of Medical Sciences, Tehran, Iran
2 Rajaie Cardiovascular and Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
3 Department of Cardiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 Department of Physiology and Physiology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

Abstract

Introduction: Human amnion-derived mesenchymal stem cells (hAMSCs) have been used in the treatment of acute myocardial infarction. In the current study, we investigated the efficacy of hAMSCs for the treatment of chronic model of myocardial ischemia and heart failure (HF) in rats.

Methods: Male Wistar rats weighing between 250 to 350 g were randomized into three groups: sham, HF control and HF+hAMSCs. For HF induction, animals were anesthetized and underwent left anterior descending artery ligation. In HF+hAMSCs group, 2×106 cells were injected into the left ventricular muscle four weeks post ischemia in the border zone of the ischemic area. Cardiac function was studied using echocardiography. Masson’s trichrome staining was used for studying tissue fibrosis. Cells were transduced with green fluorescent protein (GFP) coding lentiviral vector. Immunohistochemistry was used for detecting GFP, vascular-endothelial growth factor (VEGF) and troponin T markers in the tissue sections.

Results: Assessment of the cardiac function revealed no improvement in the myocardial function compared to the control HF group. Moreover, tissue fibrosis was similar in two groups. Immunohistochemical study revealed the homing of the injected hAMSCs to the myocardium. Cells were stained positive for VEGF and troponin T markers.

Conclusion: injection of hAMSCs 4 weeks after ischemia does not improve cardiac function and cardiac muscle fibrosis, although the cells show markers of differentiation into vascular endothelial cells and cardiomyocytes. In sum, it appears that hAMSCs are effective in the early phases of myocardial ischemia and does not offer a significant advantage in patients with chronic HF.

Please cite this article as: Gorjipour F, Hosseini-Gohari L, Alizadeh Ghavidel A, Hajimiresmaiel SJ, Naderi N, Darbandi Azar A, Pazoki-Toroudi H. Mesenchymal stem cells from human amniotic membrane differentiate into cardiomyocytes and endothelial-like cells without improving cardiac function after surgical administration in rat model of chronic heart failure. J Cardiovasc Thorac Res 2019;11(1):35-42. doi: 10.15171/jcvtr.2019.06.
First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 245

Your browser does not support the canvas element.


PDF Downloaded: 213

Your browser does not support the canvas element.